Quanta Therapeutics Inc. has identified new pyrimidine-based GTPase KRAS G12D and G12V mutant inhibitors potentially useful for the treatment of cancer.

“With the initiation of the Phase 1 clinical trial for QTX3544 in patients with KRAS G12V-driven solid tumors, we will have three KRAS inhibitor programs in the clinic focused on the most ...